Mutsumi Fukunaga

Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy

Toru Kono, Taishi Hata, Satoshi Morita et al. · Cancer Chemotherapy and Pharmacology · 2013 · 106 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Prognostic value of desmoplastic reaction characterisation in stage II colon cancer: prospective validation in a Phase 3 study (SACURA Trial)

Hideki Ueno, Megumi Ishiguro, Eiji Nakatani et al. · British Journal of Cancer · 2021 · 98 citations · Full text

Medicine, Oncology, Pathology +15

Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled phase 3 trial

Junichi Nishimura, Taroh Satoh, Mutsumi Fukunaga et al. · European Journal of Cancer · 2015 · 74 citations

Medicine, Oncology, Pharmacotherapy +12

Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial

Hirofumi Yamamoto, Kohei Murata, Mutsumi Fukunaga et al. · Clinical Cancer Research · 2016 · 43 citations

Medicine, Oncology, Surgery +14

Ephrin-A1 mRNA is associated with poor prognosis of colorectal cancer

Hirofumi Yamamoto, Mitsuyoshi Tei, Mamoru Uemura et al. · International Journal of Oncology · 2012 · 40 citations · Full text

Medicine, Molecular Biology, Oncology +17